79 Sorafenib Plus Tace for the Treatment of Advanced Hepatocellular Carcinoma – Final Results of the Socrates Trial

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma

“…The mean time of sorafenib addition to TACE was 4.5 months, thus suggesting a synergistic effect. This observation has been recently confirmed [6,7].…”

“…Interim analyses of trials [6,7] have demonstrated that the combination of sorafenib with TACE is safe. However, there is still skepticism for using this strategy, due to adverse events concerns.…”

Sorafenib for Treatment of Hepatocellular Carcinoma: A Systematic Review

“…Nine studies used sorafenib combined with other systemic therapies 33–39, 42, 43 , and 5 used sorafenib combined with locoregional therapies. 40, 41, 44, 45 Pawlik Most of the reports are relatively small case series describing preliminary results, and complete data on patient populations and outcomes often are not provided. Nevertheless, the patient populations appear similar to those of the sorafenib-alone trials, comprising predominantly men under age 70 who have advanced HCC with Child A cirrhosis.…”

Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study

“…Various studies investigate sorafenib in combination with TACE, including a Phase I trial [19], three Phase II trials [20][21][22][23] [19], an interim analyses of two Phase II studies with TACE [20,21] and one Phase II study with DEB-TACE [22,23] all suggest a similar safety profile of this combination to that of each individual treatment, but final analyses of these studies are pending.…”